Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease

Ustekinumab (UST) and vedolizumab (VDZ) are biologic therapies for moderate-to-severe Crohn's disease (CD) in patients who failed or had contraindication to anti-TNF treatment.

Source: Digestive and Liver Disease - July 22, 2022 Category: Gastroenterology Authors: Laura Melotti, Nikolas Konstantine Dussias, Marco Salice, Carlo Calabrese, Monia Baldoni, Eleonora Scaioli, Andrea Belluzzi, Elena Mazzotta, Paolo Gionchetti, Fernando Rizzello Tags: Alimentary Tract Source Type: research